Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

jCyte, Inc.

http://jcyte.com/

Latest From jCyte, Inc.

Santen CEO's Clear Vision For World 'Built On Ability To See'

CEO of Japanese ophthalmology specialist lays out clear-sighted business vision as track laid for expansion into global markets and new indications amid expiry challenges at home. New modalities are also being explored to meet needs in demanding disorders, Shigeo Taniuchi tells Scrip in an exclusive interview. 

Business Strategies Companies

Finance Watch: Arbor, Acrivon, Bit.Bio Close VC Mega-Rounds

Private Company Edition: Arbor is developing drugs based on proprietary gene editors, Acrivon is applying proteomics to precision cancer therapies, and bit.bio is producing differentiated cell products. Also, Marengo launches with $80m, Sanofi invests up to $60m in Gyroscope and Shasqi raises $50m.

Financing Innovation

Finance Watch: Prepare For September IPOs To Rebound From August Slowdown

Renaissance Capital expects an initial public offering surge in September; Biomedtracker data show financings for COVID-19 programs fell from Q1 to Q2; Revelation will merge with a special purpose acquisition corporation; Ascendis netted $379.3m in a follow-on offering; and Disc Medicine raised $90m in venture capital.

Financing Innovation

Laronde Aims To Advance Its eRNA Therapies In Eight Weeks, And Has $440m To Help

The Flagship Pioneering-founded start-up will build a “Gigabase Factory” to go from idea to in vivo proof of concept within eight weeks by rapidly manufacturing and running preclinical tests for multiple constructs at once. 

Financing Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Medical Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
UsernamePublicRestriction

Register